MX2010009642A - Metodos de tratamiento utilizando infusion continua prolongada de belinostat. - Google Patents

Metodos de tratamiento utilizando infusion continua prolongada de belinostat.

Info

Publication number
MX2010009642A
MX2010009642A MX2010009642A MX2010009642A MX2010009642A MX 2010009642 A MX2010009642 A MX 2010009642A MX 2010009642 A MX2010009642 A MX 2010009642A MX 2010009642 A MX2010009642 A MX 2010009642A MX 2010009642 A MX2010009642 A MX 2010009642A
Authority
MX
Mexico
Prior art keywords
prolonged continuous
belinostat
methods
continuous infusion
treatment employing
Prior art date
Application number
MX2010009642A
Other languages
English (en)
Spanish (es)
Inventor
Maxwell Sehested
Peter Buhl Jensen
Nis Niseen
Original Assignee
Topotarget As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Topotarget As filed Critical Topotarget As
Publication of MX2010009642A publication Critical patent/MX2010009642A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MX2010009642A 2008-03-07 2009-03-06 Metodos de tratamiento utilizando infusion continua prolongada de belinostat. MX2010009642A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3463508P 2008-03-07 2008-03-07
PCT/IB2009/005044 WO2009109861A1 (en) 2008-03-07 2009-03-06 Methods of treatment employing prolonged continuous infusion of belinostat

Publications (1)

Publication Number Publication Date
MX2010009642A true MX2010009642A (es) 2010-09-22

Family

ID=40691318

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010009642A MX2010009642A (es) 2008-03-07 2009-03-06 Metodos de tratamiento utilizando infusion continua prolongada de belinostat.

Country Status (14)

Country Link
US (1) US20110003777A1 (enExample)
EP (1) EP2262493B1 (enExample)
JP (1) JP5615189B2 (enExample)
CN (1) CN102083428A (enExample)
AU (1) AU2009220942B2 (enExample)
CA (1) CA2717207A1 (enExample)
DK (1) DK2262493T3 (enExample)
EA (1) EA022880B1 (enExample)
ES (1) ES2536208T3 (enExample)
MX (1) MX2010009642A (enExample)
PL (1) PL2262493T3 (enExample)
PT (1) PT2262493E (enExample)
SI (1) SI2262493T1 (enExample)
WO (1) WO2009109861A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011064663A1 (en) 2009-11-25 2011-06-03 Festuccia, Claudio Combination treatment employing belinostat and bicalutamide
CN109077995A (zh) * 2012-04-27 2018-12-25 太阳医药工业有限公司 即可灌注的吉西他滨溶液
CN103839548B (zh) * 2012-11-26 2018-06-01 腾讯科技（北京）有限公司 一种语音交互方法、装置、系统和移动终端

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4642316A (en) * 1985-05-20 1987-02-10 Warner-Lambert Company Parenteral phenytoin preparations
US6071923A (en) * 1994-09-16 2000-06-06 Bar-Ilan University Retinoyloxy aryl-substituted alkylene butyrates useful for the treatment of cancer and other proliferative diseases
US20020025921A1 (en) * 1999-07-26 2002-02-28 Petito George D. Composition and method for growing, protecting, and healing tissues and cells
JP2002527449A (ja) * 1998-10-13 2002-08-27 藤沢薬品工業株式会社 環状テトラペプチド化合物およびその用途
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
CN1308347C (zh) * 1999-04-28 2007-04-04 德克萨斯大学董事会 用于通过选择性抑制vegf来治疗癌症的组合物和方法
US6541661B1 (en) * 1999-11-23 2003-04-01 Methylgene, Inc. Inhibitors of histone deacetylase
EP2083005A1 (en) * 2000-09-29 2009-07-29 TopoTarget UK Limited Carbamic acid compounds comprising an amide linkage as HDAC inhibitors
GB0023983D0 (en) * 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
WO2002030879A2 (en) * 2000-09-29 2002-04-18 Prolifix Limited Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
US20050119305A1 (en) * 2001-03-21 2005-06-02 Masao Naka Il-6 production inhibitors
PL368129A1 (en) * 2001-08-09 2005-03-21 Ono Pharmaceutical Co, Ltd. Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
US6897220B2 (en) * 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
US7041699B2 (en) * 2002-01-11 2006-05-09 Matthias Rath Nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer
US20050288227A1 (en) * 2002-02-15 2005-12-29 Marks Paul A Use of thioredoxin measurements for diagnostics and treatments
EP1482962A4 (en) * 2002-02-15 2009-12-23 Sloan Kettering Inst Cancer METHOD OF TREATING THIOREDOXIN-MEDIATED DISEASES (TRX)
US20070060614A1 (en) * 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
EP2322160A1 (en) * 2002-03-04 2011-05-18 Merck HDAC Research, LLC Methods of inducing terminal differentiation
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
WO2003087066A1 (en) * 2002-04-11 2003-10-23 Sk Chemicals, Co., Ltd. α,β-UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS
MXPA04010199A (es) * 2002-04-15 2005-07-05 Sloan Kettering Inst Cancer Terapia en combinacion para el tratamiento de cancer.
US8883148B2 (en) * 2002-04-26 2014-11-11 Asan Laboratories Company (Cayman), Limited Prevention of joint destruction
US20080004311A1 (en) * 2002-11-12 2008-01-03 Alcon, Inc. Histone deacetylase inhibitors for treating degenerative diseases of the eye
WO2004064727A2 (en) * 2003-01-16 2004-08-05 Georgetown University Method of cancer treatment using hdac inhibitors
CA2518318A1 (en) * 2003-03-17 2004-09-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20040220242A1 (en) * 2003-05-02 2004-11-04 Leland Shapiro Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions
EP1491188A1 (en) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topical use of valproic acid for the prevention or treatment of skin disorders
PT1663194E (pt) * 2003-08-26 2010-07-06 Merck Hdac Res Llc Utilizaã†o de saha para o tratamento de mesotelioma
US20060270016A1 (en) * 2003-11-14 2006-11-30 Holm Per S Novel adenoviruses, nucleic acids that code for the same and the use of said viruses
WO2005051430A1 (de) * 2003-11-14 2005-06-09 Per Sonne Holm Neue verwendung von adenoviren und dafür codierenden nukleinsäuren
GB0401876D0 (en) * 2004-01-28 2004-03-03 Vereniging Het Nl Kanker I New use for cancer antigen
EP1725873B1 (en) * 2004-02-27 2009-07-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pharmacodynamic assays using flow cytometry.
EP1591109B1 (en) * 2004-04-30 2008-07-02 TopoTarget Germany AG Formulation comprising histone deacetylase inhibitor exhibiting biphasic release
EP1787657A1 (en) * 2004-08-06 2007-05-23 Ono Pharmaceutical Co., Ltd. Therapeutic agent for psychoneurotic disease
WO2006016680A1 (en) * 2004-08-09 2006-02-16 Astellas Pharma Inc. Hydroxyamide compounds having activity as inhibitors of histone deacetylase (hdac)
WO2006060382A2 (en) * 2004-11-30 2006-06-08 Trustees Of The University Of Pennsylvania Use of hdac and/or dnmt inhibitors for treatment of ischemic injury
EP1830864A2 (de) * 2004-12-31 2007-09-12 Per Sonne Holm E1 -minus adenoviren und deren verwendung
KR101346886B1 (ko) * 2005-01-21 2014-01-02 아스텍스 테라퓨틱스 리미티드 제약 화합물
CA2596210C (en) * 2005-02-03 2014-07-08 Topotarget Uk Limited Combination therapies using hdac inhibitors
US20060229237A1 (en) * 2005-04-07 2006-10-12 Yih-Lin Chung Treatment of gastrointestinal distress
GB0509225D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
ES2380887T3 (es) * 2005-05-13 2012-05-21 Topotarget Uk Limited Formulaciones farmacéuticas de inhibidores de la HDAC
EP1743654A1 (en) * 2005-07-15 2007-01-17 TopoTarget Germany AG Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
JP2009504751A (ja) * 2005-08-19 2009-02-05 アメリカ合衆国 ヒストンデアセチラーゼ阻害薬の局所製剤及びその使用方法
RU2008108221A (ru) * 2005-09-07 2009-10-20 Плекссикон, Инк. (Us) Соединения, активные в отношении ppar (рецепторов активаторов пролиферации пероксисом)
US8828392B2 (en) * 2005-11-10 2014-09-09 Topotarget Uk Limited Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent
US8445198B2 (en) * 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
KR20080103977A (ko) * 2006-02-22 2008-11-28 4에스체 악티엔게젤샤프트 Ｅｇ５ 키네신 조절자로서 인돌로피리딘
US8530493B2 (en) * 2006-02-22 2013-09-10 4Sc Ag Indolopyridines as Eg5 kinesin modulators
EP1839656A1 (en) * 2006-03-31 2007-10-03 TopoTarget Germany AG Use of valproic acid for the topical treatment of mild to moderate acne vulgaris
WO2007129062A1 (en) * 2006-05-08 2007-11-15 Astex Therapeutics Limited Pharmaceutical combinations of diazole derivatives for cancer treatment
EP2040731A4 (en) * 2006-06-09 2010-05-19 Merrion Res Iii Ltd SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING AN ACTIVATOR
WO2008011603A2 (en) * 2006-07-20 2008-01-24 Wisconsin Alumni Research Foundation Modulating notch1 signaling pathway for treating neuroendocrine tumors
WO2008058287A1 (en) * 2006-11-10 2008-05-15 Syndax Pharmaceuticals, Inc. COMBINATION OF ERα+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
US8796330B2 (en) * 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
US7915245B2 (en) * 2007-02-01 2011-03-29 The Board Of Regents Of The University Of Texas System Methods and compositions of trail-death receptor agonists/activators
US8012695B2 (en) * 2007-02-14 2011-09-06 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to promoter regulation by MUC1 and KLF proteins
WO2008136838A1 (en) * 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
GB2454118B (en) * 2007-06-06 2010-06-02 Univ Maryland Hdac inhibitors and hormone targeted drugs for the treatment of cancer
WO2009146034A2 (en) * 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
US20090270497A1 (en) * 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
US8637554B2 (en) * 2008-05-07 2014-01-28 The Trustees Of The University Of Pennsylvania Methods for treating thyroid cancer

Also Published As

Publication number Publication date
PT2262493E (pt) 2015-06-02
AU2009220942A8 (en) 2012-08-30
CA2717207A1 (en) 2009-09-11
WO2009109861A1 (en) 2009-09-11
AU2009220942A1 (en) 2009-09-11
JP2011513378A (ja) 2011-04-28
EA201070913A1 (ru) 2011-04-29
US20110003777A1 (en) 2011-01-06
CN102083428A (zh) 2011-06-01
EP2262493B1 (en) 2015-02-25
PL2262493T3 (pl) 2015-08-31
DK2262493T3 (en) 2015-04-27
SI2262493T1 (sl) 2015-07-31
EA022880B1 (ru) 2016-03-31
AU2009220942B2 (en) 2015-05-28
JP5615189B2 (ja) 2014-10-29
EP2262493A1 (en) 2010-12-22
HK1152247A1 (en) 2012-02-24
ES2536208T3 (es) 2015-05-21

Similar Documents

Publication Publication Date Title
EA201000673A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИЗМЕРЕНИЯ АКТИВАЦИИ Wnt И ДЛЯ ЛЕЧЕНИЯ Wnt-ОПОСРЕДОВАННЫХ РАКОВЫХ ЗАБОЛЕВАНИЙ
MX2023002076A (es) Conjugado de polimero util para tratar tumores ocasionados por disfuncion metabolica.
PH12018502259A1 (en) Isoquinolin-3-yl carboxamides and preparation and use thereof
PH12017502079A1 (en) Treatment of beta-thalassemia using actrii ligand traps
EP4272757A3 (en) Modified nk-92 cells for treating cancer
MX370487B (es) Inhibidores de 3-(benzo-imidazol-2-il)-indazol de la senda de señalización de wnt y usos terapéuticos de los mismos.
EP2294184A4 (en) TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION WITH THE HELP OF COMBINED THERAPY
PH12016501835A1 (en) 5-substituted indazole -3- carboxamides and preparation and use thereof
MX2022001310A (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo.
NZ707859A (en) Inhibitors of sodium glucose cotransporter 1
WO2011146879A3 (en) Methods and compositions related to modulating autophagy
MX2013000301A (es) Factores quimericos de coagulacion.
PH12017501588A1 (en) Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
IN2014CN02646A (enExample)
MY186456A (en) Quinazoline carboxamide azetidines
CR20220207A (es) Compuestos terapéuticos y métodos de uso
CR20200291A (es) Composiciones y métodos para el tratamiento de enfermedades metabólicas
MX2015003800A (es) Terapia de combinacion mediante el uso de belinostat y trabetedina.
PH12020551300A1 (en) 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof
ZA202002936B (en) Phenoxy acids for the treatment of neuromuscular disorders
MX2010009642A (es) Metodos de tratamiento utilizando infusion continua prolongada de belinostat.
CA3085227C (en) Phenoxiacetic acids for the treatment of neuromuscular disorders
EA201170885A1 (ru) Новые производные ретиноидов, обладающие цитотоксическими и/или антиангиогенными свойствами
RU2013130449A (ru) Способ комбинированного лечения рака прямой кишки
EP4470624A3 (en) Methods of administering anti-fibrotic therapy

Legal Events

Date Code Title Description
FG Grant or registration